Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374049 · ClinicalTrials.gov registry record · Phase 1
MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
A Phase 1 study, sponsored by Olivera Finn.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00374049: Completed Phase 1 study, sponsored by Olivera Finn.
NCT00374049 is a Phase 1 study that has completed, run by Olivera Finn. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00374049, a Phase 1 study, has completed, sponsored by Olivera Finn.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also known as HiltonolTM, in boosting the body's immune system's response to an experimental vaccine therapy (called the MUC-1 vaccine).
Interventions
- DRUG MUC_1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT00374049 record still lists
NCT00374049 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which MUC_1 is the first listed.
NCT00374049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00374049 about?
NCT00374049 is a clinical study titled "MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer". The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also known as HiltonolTM, in boosting the body's immune system's response to an experimental vaccine therapy (called the MUC-1 vaccine).
What is the current status of trial NCT00374049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00374049?
The interventions under investigation include: MUC_1 (DRUG).
Who is sponsoring clinical trial NCT00374049?
This trial is sponsored by Olivera Finn, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00374049's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia